As pioneers in the discovery and development of novel products for the treatment of cancer and serious neurological disorders, Guilford is dedicated to “making a difference by making new medicines.” In our five year history, we have already established a strong track record of success, bringing a product, GLIADEL Wafer, to market, and building a substantial pharmaceutical pipeline with multiple product development opportunities servicing potentially large and growing markets.

Turning technology into products... Translating exciting discoveries into successful commercial products The potential of our various programs to slow down, stop and possibly reverse the course of serious human disease is certainly exciting, but equally important in the discovery and development of these “new medicines” is our commitment to building a successful and sustainable business. To accomplish this, we focus on “monetizing our technology,” or translating exciting discoveries into successful commercial opportunities. Partnerships like the ones we have with Rhône-Poulenc Rorer and Amgen have allowed us to expand our pipeline by developing other promising programs like our NAALADase and PARP programs, while still maintaining significant upside potential for the Company. Being strategic... Balancing the potential of novel drug delivery and therapeutic technologies Focusing on both drug delivery and pharmaceutical development enables us to balance a spectrum of lower-risk near-term drug delivery products with potentially higher-yield novel pharmaceutical products. This “Portfolio Management Approach” permits us to not only manage risk for our shareholders, but to leverage our existing infrastructure and regulatory expertise in drug development in order to introduce new products to market. Equipping ourselves for success... Assembling the requisite human, technical and financial capital Sufficient technical, human and financial capital is essential for success. We are proud that Guilford attracts some of the brightest minds in the pharmaceutical business and neuroscience from around the world. Having the financial resources to advance these programs is another distinguishing feature of our Company. In contrast to many other biotech companies, Guilford has a strong balance sheet and an admirable track record of astute financial management. This combination of technical, human and financial capital is the cornerstone of our current and future success. Seizing opportunities... Developing product candidates with multiple product development opportunities Of course, not all new drug candidates will succeed to commercialization. That’s why we believe in having multiple product development opportunities. With a number of drug delivery and small molecule pharmaceutical programs in development at Guilford, each with multiple potential disease applications, we believe we have enhanced the probability of success for our Company.